#China #Beijing #Hepatitis B #Hepatitis D #Libevitug

Hepatitis D: An Overlooked Challenge

On World Hepatitis Day 2026, there is an urgent call to address the barriers hindering testing, treatment, and care for hepatitis, particularly focusing on hepatitis D (HDV), the most severe form of viral hepatitis. Approximately 12 million individuals globally are estimated to be infected with HDV, which only affects people already living with hepatitis B (HBV). Despite this significant number, awareness and understanding of hepatitis D remain lacking, largely overshadowed by the more recognized hepatitis B and C.

The Global Impact of Hepatitis D

Central Asia, especially regions like Mongolia, western China, Afghanistan, and parts of the Middle East, shows alarming rates of HDV infections. However, due to insufficient national epidemiological data, the true extent of the problem may be understated. For instance, studies have indicated that HDV antibodies are present in about 13% and 15% of individuals with hepatitis B in Kazakhstan and Kyrgyzstan, respectively. A staggering 84% of hepatitis B patients in a recent Uzbekistan hospital study tested positive for HDV antibodies.

Given the rapid progression of hepatitis D, early diagnosis becomes crucial. Research highlights that HDV can escalate to liver cirrhosis within five years and potentially develop into liver cancer within ten years. Unfortunately, access to confirmatory testing for HDV RNA remains limited in many low- and middle-income countries, rendering many infections undiagnosed and complicating accurate assessments of the situation.

Treatment Limitations

Treatment options for hepatitis D are equally constrained. As of July 2026, only two therapies targeting HDV have received regulatory approval worldwide, with none available in Central Asia. Consequently, patients often seek medical assistance from cities like Beijing and Urumqi in China. In January 2026, Libevitug, a groundbreaking medication received conditional approval in China, marking it as the first specific treatment for chronic hepatitis D and the first monoclonal antibody authorized for viral hepatitis treatment globally. Clinical trials demonstrated its effectiveness in improving liver stiffness, a critical indicator of liver health.

The Need for Awareness and Accessibility

To bring hepatitis D out of the shadows and ensure more individuals receive timely diagnosis and care, increased public awareness is imperative. Expanding testing capabilities and fostering scientific knowledge exchange are paramount. Bin Chen, CEO of Huahui Health, the developer of Libevitug, emphasized, “Improving hepatitis D treatment will require sustained collaboration throughout the region.”

By collaborating with partners in scientific exchange and clinical research, progress can eventually benefit a broader patient population. It’s essential to prioritize hepatitis D within health agendas worldwide to confront this underestimated threat effectively. As we strive for better health outcomes, the focus must be on eliminating barriers and enhancing access to diagnosis and treatment options for all affected individuals.